An observational study in Multiple Myeloma, Multiple Myeloma Progression and Monoclonal Gammopathy of Undetermined Significance (MGUS), sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 30 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Wake Forest University Health Sciences · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Multiple Myeloma by Wake Forest University Health Sciences — 5 open to participants now, 7 under way, none of them phase 3. Multiple Myeloma · Wake Forest University Health Sciences.
Among the 24 studies in Multiple Myeloma by Wake Forest University Health Sciences, this one is one of 2 that started in 2025, is one of 7 observational ones, and was the 22nd registered.
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →5 of the 24 studies in Multiple Myeloma by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 40–49 · Healthy volunteers
Wake Forest University Health Sciences · Sites in United States
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 18–120
By country, each count listing its studies:
Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 30 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9
First in 2001; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,665 is above the median of 150 across 486 observational studies indexed under Multiple Myeloma.
Median enrollment 18 across the 17 interventional studies, 54 across the 7 observational. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
Wake Forest University Health Sciences is the lead sponsor of 1,353 studies on the registry; 199 are open to participants now.
Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.
2 of the studies in Multiple Myeloma by Wake Forest University Health Sciences that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01890486Wake Forest University Health SciencesThe Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen | 2026-12 |
| NCT06870760Wake Forest University Health SciencesPre-malignant States to Hematologic Malignancies in Firefighters | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies in Multiple Myeloma by Wake Forest University Health Sciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.
The CHAAMP Internal Pilot is a pilot and feasibility study conducted to evaluate the feasibility of the trial methods before a full-scale screening effort is launched. High risk individuals 30 years of age or older residing in Charlotte or surrounding area will be screened for MGUS over one-year period with a target enrollment of 1665 participants. Individuals screening positive for monoclonal gammopathy will be provided a clinic referral for further diagnostic evaluation to confirm MGUS, SMM, or other PCD-related disorder, and will be given the opportunity to consent for the Longitudinal portion of the study. Participants diagnosed with MGUS and smoldering multiple myeloma will be prospectively followed for 10 years per protocol. Participants diagnosed with other plasma cell disorders will have their diagnosis and baseline data captured in the registry and followed for overall survival only.
High risk individuals with age greater than or equal to 30 years at the time of consent, residing in the Charlotte, NC or surrounding areas.
SCREENING Inclusion Criteria:
Either:
SCREENING Exclusion Criteria:
LONGITUDINAL Inclusion Criteria:
LONGITUDINAL Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants diagnosed with MGUS and smoldering multiple myeloma
Other: Blood draw for the laboratory assessment
Participants diagnosed with other plasma cell disorders
Other: Blood draw for the laboratory assessment
Screening blood sample collection to test for MGUS
Number of Participants who were Enrolled
Determined for each potential participant approached to participate in this study (pre-screened), indicating whether or not the participant was enrolled (underwent blood draw to test for monoclonal gammopathy).
Time frame: Baseline, for an accrual period of one year
Monoclonal Gammopathy at Screening
A categorical variable will be determined for each enrolled participant indicating whether or not the participant had monoclonal gammopathy identified on screening blood draw, or if the test results were indeterminate (options: monoclonal gammopathy, no monoclonal gammopathy, unknown/indeterminant test results).
Time frame: From enrollment to availability of lab results, approximately 30 days
PCD Diagnosis at Screening
PCD diagnosis at screening will be determined as a nominal categorical variable indicating the participant's PCD diagnosis at screening. The categorical variable will include the following factor levels: monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), multiple myeloma (MM), AL amyloidosis, other PCD/ lymphoproliferative disorder, monoclonal gammopathy with unknown diagnosis, or no monoclonal gammopathy. Reason for unknown diagnosis may be due to non-definitive results, no results due to lab error, sampling issues, or participant did not get complete diagnostic work up.
Time frame: From enrollment to completion of diagnostic work up, approximately 90 days
PCD Diagnosis During Follow-Up
PCD diagnosis during follow-up will be determined as a categorical variable for each new PCD diagnosis indicating whether the participant had the type of PCD diagnosed over the course of the follow up period on the study. The types of new PCD diagnosis will include SMM, MM, AL amyloidosis, and other PCD diagnosis, per diagnostic criteria as defined in Appendix A. Date of each new PCD diagnosis will also be captured.
Time frame: From enrollment to completion of follow up (10 years)
CRAB Criteria at MM Diagnosis
CRAB criteria at MM diagnosis are defined as a binary variable indicating whether the participant had CRAB criteria at the time of MM diagnosis. CRAB criteria include hypercalcemia, renal insufficiency, anemia, or bone lesions as defined per IMWG. This will be evaluated only in the subjects diagnosed with MM during longitudinal follow-up
Time frame: From enrollment to completion of follow up (10 years)
Time to MM Diagnosis
Time to MM diagnosis is defined as the duration of time from MGUS diagnosis (or SMM diagnosis for participants diagnosed with SMM at screening) to diagnosis of MM per IMWG criteria. The date of MM diagnosis is the date of the first assessment that identified MM. If the participant died without a diagnosis of MM, time to MM diagnosis will be calculated at the date of death, with death as a competing risk event. For surviving subjects who do not have documented MM diagnosis, time to MM diagnosis will be censored at the date of the last documented disease evaluation that confirmed no MM diagnosis.
Time frame: From enrollment to completion of follow up (10 years)
Number of Participants who Interacted with a Community Champion
Interaction with a community champion will be captured for each potential participant as a binary variable indicating whether or not the potential participant interacted with a study-associated community champion prior to enrollment or prior to declining participation. This will be captured via the "Interaction with Community Champion Survey".
Time frame: Baseline
Impact of Interaction with a Community Champion
Community champion impact will be reported by each enrolled participant that interacted with a community champion. It will be captured as an ordered categorical variable (5-point Likert scale) indicating the level of impact that the community champion had on the participant's decision to participate in the study. This will be captured via the "Interaction with Community Champion Survey".
Time frame: Baseline
Number of MGUS Participants who Participate in Longitudinal Portion of Study
For each participant that is determined to have MGUS at screening, a binary variable will be captured, indicating whether or not the participant consented to be followed longitudinally in the longitudinal portion of the study.
Time frame: From enrollment to presentation of second (longitudinal) consent, approximately 90 days
Barriers to Screening Participation
For participants who are approached but do not verbally agree to participation in the study, verbal reason for declining study participation will be reported and captured via a "Barriers to Participation Survey" that includes multi-select discrete options as well as an "Other" reason with free text option.
Time frame: Baseline
Barriers to Longitudinal Participation
For participants with monoclonal gammopathy identified during screening but who do not agree to participate in the longitudinal portion of the study, reason for declining longitudinal participation will be reported and captured via a "Barriers to Participation Survey" that includes multi-select discrete options as well as an "Other" with free text option.
Time frame: From enrollment to presentation of second (longitudinal) consent, approximately 90 days
Psychological Counseling Referral
For each participant with monoclonal gammopathy identified during screening, a binary variable indicating whether a psychological counseling referral was accepted after learning of positive results.
Time frame: From enrollment to completion of diagnostic work up, approximately 90 days.
Light Chain MGUS Diagnosis at Screening
Determined as a binary variable indicating whether the participant had light chain MGUS diagnosis at screening. Three definitions of light chain MGUS (with applicable reference ranges for FLC ratio, involved FLC) will be utilized to evaluate this endpoint: standard IMWG diagnostic criteria \[with FLC ranges from Katzmann et al (2002)\], iStop MM criteria incorporating age and renal function \[Long et al (2025)\], and Dana Farber Cancer Institute criteria incorporating race \[Bertamini et al (2025)\].
Time frame: From enrollment to completion of diagnostic work up, approximately 90 days.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Jan 2035, 118 months after the start.
Of 173 non-industry observational studies under Multiple Myeloma, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 31. This study's planned 118 months is above that.
Counting every sponsor, half of 239 studies reached it within 57 months; a quarter within 30 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wake Forest University Health Sciences →